Medtech

Company Events

Vantage logo

Darzalex's ambitions extend beyond Maia

Data from quad therapy and a subcutaneous formulation could resuscitate enthusiasm even if the US government shutdown delays Darzalex's upcoming first-line approval.

Interviews

Vantage logo

Albireo comes up to IBAT in Nash

Albireo is taking aim at yet another Nash target, but Shire and Glaxosmithkline have already ditched projects with similar mechanisms.

Vantage Homepage